[1]
Garbayo E, Pascual-Gil S, Rodríguez-Nogales C, Saludas L, Estella-Hermoso de Mendoza A, Blanco-Prieto MJ. Nanomedicine and drug delivery systems in cancer and regenerative medicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2020; 12(5): e1637.
[http://dx.doi.org/10.1002/wnan.1637] [PMID: 32351045]
[http://dx.doi.org/10.1002/wnan.1637] [PMID: 32351045]
[2]
Blanco-Prieto MJ. Editorial. Int J Pharm 2013; 440(1): 1-2.
[http://dx.doi.org/10.1016/j.ijpharm.2012.10.001] [PMID: 23043961]
[http://dx.doi.org/10.1016/j.ijpharm.2012.10.001] [PMID: 23043961]
[3]
Ravi Kumar MN, Blanco-Prieto MJ, Waterhouse DN. Nanotheraputics. Cancer Lett 2013; 334(2): 155-6.
[http://dx.doi.org/10.1016/j.canlet.2013.02.047] [PMID: 23523611]
[http://dx.doi.org/10.1016/j.canlet.2013.02.047] [PMID: 23523611]
[4]
Rodríguez-Nogales C, González-Fernández Y, Aldaz A, Couvreur P, Blanco-Prieto MJ. Nanomedicines for Pediatric Cancers. ACS Nano 2018; 12(8): 7482-96.
[http://dx.doi.org/10.1021/acsnano.8b03684] [PMID: 30071163]
[http://dx.doi.org/10.1021/acsnano.8b03684] [PMID: 30071163]
[5]
Saludas L, Oliveira CC, Roncal C, et al. Extracellular Vesicle-Based Therapeutics for Heart Repair. Nanomaterials (Basel) 2021; 11(3): 570.
[http://dx.doi.org/10.3390/nano11030570] [PMID: 33668836] [PMCID: PMC7996323]
[http://dx.doi.org/10.3390/nano11030570] [PMID: 33668836] [PMCID: PMC7996323]
[6]
Rodríguez-Nogales C, Noguera R, Couvreur P, Blanco-Prieto MJ. Therapeutic Opportunities in Neuroblastoma Using Nanotechnology. J Pharmacol Exp Ther 2019; 370(3): 625-35.
[http://dx.doi.org/10.1124/jpet.118.255067] [PMID: 30635473]
[http://dx.doi.org/10.1124/jpet.118.255067] [PMID: 30635473]
[7]
Luque-Michel E, Lemaire L, Blanco-Prieto MJ. SPION and doxorubicin-loaded polymeric nanocarriers for glioblastoma theranostics. Drug Deliv Transl Res 2021; 11(2): 515-23.
[http://dx.doi.org/10.1007/s13346-020-00880-8] [PMID: 33405212]
[http://dx.doi.org/10.1007/s13346-020-00880-8] [PMID: 33405212]